Skip to content

Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Chronic Insomnia Disorde

Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Chronic Insomnia Disorde

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107237
Enrollment
Unknown
Registered
2025-08-06
Start date
2025-08-06
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Insomnia Disorder

Interventions

Repetitive Transcranial Magnetic Stimulation (rTMS) Group (Group R):Repetitive Transcranial Magnetic Stimulation (rTMS)
Stellate Ganglion Block Group (Group S):Stellate Ganglion Block

Sponsors

RUIJIN-HAINAN HOSPITAL SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE(Hainan Boao Research Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 150 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with chronic insomnia disorder according to the International Classification of Sleep Disorders (3rd edition) by the American Academy of Sleep Medicine (AASM); 2.agree and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.History of any drug abuse, severe neurological or psychiatric illnesses; 2.History of neurosurgical operations or head trauma; 3.pregnancy; 4.People with various electronic medical treatment or auxiliary devices implanted in the body; 5.Individuals wearing or currently using various medical electronic devices or instruments (such as ambulatory electrocardiographs, electronic kidneys, cochlear implants, etc.); 6.Contraindications to magnetic resonance imaging (MRI) or refusal to complete MRI scanning;

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index (PSQI);

Secondary

MeasureTime frame
Polysomnography parameters;Sleep diary indicators;Salivary cortisol, serum cortisol, 5-HT (5-hydroxytryptamine), BDNF (brain-derived neurotrophic factor), proBDNF (pro-brain-derived neurotrophic factor), tPA (tissue plasminogen activator), NPS (neuro;Monitoring parameters of sleep monitoring bracelet;Adverse events such as headache, dizziness, and local scalp discomfort;Brain network functional connectivity;Athens Insomnia Scale (AIS);Montreal Cognitive Assessment (MoCA);Hamilton Depression/Anxiety Rating Scale (HAMD/HAMA);

Countries

China

Contacts

Public ContactZhang Liyun

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

zlzhangliyun@126.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026